Summary & Overview
HCPCS J9311: Rituximab 10 mg with Hyaluronidase Injection
HCPCS Level II code J9311 designates an injection of rituximab 10 mg combined with hyaluronidase, representing a biologic therapy formulation intended for facilitated subcutaneous or injectable administration. Nationally, this code matters because it captures billing for a widely used monoclonal antibody therapy in oncology, hematology, and certain autoimmune conditions where rituximab is indicated, and it affects reimbursement, site-of-service classification, and utilization tracking for high-cost specialty drugs.
Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find benchmarks for payer coverage approaches, typical allowed amounts and site-of-service implications where available, and an overview of clinical context for use of rituximab with hyaluronidase. The publication summarizes common coding considerations, payer variation in coverage policies, and implications for outpatient infusion centers and oncology clinics.
This summary provides a concise reference for billing, clinical, and policy stakeholders seeking national-level context on coding and reimbursement treatment for this injectable biologic formulation. Data not available in the input is noted where applicable in detailed sections.
Billing Code Overview
HCPCS Level II code J9311 describes an injection formulation of rituximab at 10 mg with hyaluronidase. This code represents a biologic combination product administered as an injectable medication, commonly used in outpatient infusion or oncology clinic settings for indications that employ rituximab therapy where a subcutaneous or facilitated subcutaneous formulation is delivered.
Service type: Injectable biologic therapy
Typical site of service: Outpatient infusion center or oncology/hematology clinic
Clinical & Coding Specifications
Clinical Context
A typical patient is a 62-year-old female with relapsed, CD20-positive diffuse large B-cell lymphoma referred to an oncology infusion center for subcutaneous rituximab and hyaluronidase administration. The patient presents for scheduled therapy after baseline evaluation by the hematology-oncology team, including recent labs (CBC, CMP), review of infusion history, and assessment for infusion reactions. The clinical workflow includes: pre-visit medication reconciliation and allergy check; verification of indication and prior authorization; baseline vital signs and weight; venous access assessment (peripheral IV or implanted port); preparation of J9311 (rituximab 10 mg with hyaluronidase) by pharmacy per USP <797> and manufacturer directions; point-of-care verification and barcode scanning; administration by an experienced infusion nurse with monitoring for hypersensitivity and local injection-site reactions; documentation of lot number, expiration, dose, route (subcutaneous), and any modifier(s); post‑administration observation for the recommended period; and scheduling of follow-up oncology visits and subsequent cycles. Typical site of service is an outpatient infusion center, oncology clinic, or hospital outpatient department. Service type is subcutaneous biologic injection (rituximab with hyaluronidase).
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
11 | Surgical or procedural service performed by the physician |